Australasian Biotechnology,
Volume 8 Number 5, September/October 1998, pp. 303-305
CONFERENCE PAPER
Biotechnologies Applied to the Production of Pharmaceuticals and Vaccines: A Summary
A. Sasson,
Code Number:AU98039
Sizes of Files:
Text: 13K
Graphics: No associated graphics files
In 1973, Stanley Cohen of Stanford University, Herbert Boyer of the University of
California Medical School (San Francisco), and their colleagues succeeded in designing the
method for the transfer of a gene from one organism to another, thus establishing the basis of
recombinant DNA technology. In 1981, the first US-approved biotechnology product reached
consumers: a monoclonal antibody-based diagnostic test kit. The following year, the first
recombinant DNA pharmaceutical, Genentech Incs.'s (Eli Lilly & Co.) Humulin®,
recombinant human insulin, was approved for sale in the USA and United Kingdom. That
same year, the first recombinant animal vaccine against colibacillosis was approved in Europe.
Copyright 1998 Australian Biotechnology Association Ltd.
